C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
2.260
-0.030 (-1.31%)
Jul 25, 2025, 4:00 PM - Market closed
C4 Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2020 |
Cash & Equivalents | 51.29 | 55.5 | 126.59 | 29.75 | 76.12 | 181.73 | Upgrade |
Short-Term Investments | 163.79 | 189.41 | 127.09 | 246.4 | 233.16 | 189.96 | Upgrade |
Cash & Short-Term Investments | 215.09 | 244.9 | 253.68 | 276.15 | 309.28 | 371.69 | Upgrade |
Cash Growth | -16.70% | -3.46% | -8.14% | -10.71% | -16.79% | 310.48% | Upgrade |
Receivables | 8.03 | 3.1 | 11.8 | 1.47 | 5.72 | 4.48 | Upgrade |
Prepaid Expenses | 9.42 | 9.76 | 5.71 | 9.93 | 10.69 | 4.84 | Upgrade |
Total Current Assets | 232.54 | 257.77 | 271.19 | 287.56 | 325.69 | 381.01 | Upgrade |
Property, Plant & Equipment | 61.36 | 63.38 | 71.09 | 77.52 | 35.05 | 16.55 | Upgrade |
Long-Term Investments | 19.62 | 22.36 | 28.01 | 60.96 | 142.2 | - | Upgrade |
Other Long-Term Assets | 6.01 | 6.1 | 6.17 | 4.81 | 3.82 | 2.58 | Upgrade |
Total Assets | 319.52 | 349.6 | 376.45 | 430.84 | 506.77 | 400.14 | Upgrade |
Accounts Payable | 0.68 | 1.33 | 1.45 | 1.17 | 4.51 | 5.68 | Upgrade |
Accrued Expenses | 10.75 | 17.49 | 15.49 | 16.66 | 13.19 | 9.06 | Upgrade |
Current Portion of Long-Term Debt | - | - | - | 2.29 | - | - | Upgrade |
Current Portion of Leases | 5.92 | 5.77 | 5.22 | 4.7 | 1.33 | 1.04 | Upgrade |
Current Unearned Revenue | 21.59 | 18.71 | 15.47 | 16.62 | 31.8 | 27.6 | Upgrade |
Other Current Liabilities | 1.88 | 1.87 | 5.14 | 3.11 | 0.41 | 0.47 | Upgrade |
Total Current Liabilities | 40.82 | 45.18 | 42.77 | 44.55 | 51.25 | 43.85 | Upgrade |
Long-Term Debt | - | - | - | 9.2 | 10.77 | 10.05 | Upgrade |
Long-Term Leases | 58.45 | 59.98 | 65.76 | 70.97 | 30.78 | 11.83 | Upgrade |
Long-Term Unearned Revenue | 25.12 | 28.46 | 21.81 | 16.9 | 24.37 | 53.62 | Upgrade |
Total Liabilities | 124.38 | 133.62 | 130.34 | 141.61 | 117.16 | 119.35 | Upgrade |
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0 | Upgrade |
Additional Paid-In Capital | 855.11 | 849.63 | 774.62 | 689.26 | 658.09 | 464.6 | Upgrade |
Retained Earnings | -660.02 | -633.7 | -528.38 | -395.89 | -267.72 | -183.82 | Upgrade |
Comprehensive Income & Other | 0.04 | 0.05 | -0.13 | -4.14 | -0.78 | 0.01 | Upgrade |
Total Common Equity | 195.14 | 215.99 | 246.11 | 289.23 | 389.61 | 280.79 | Upgrade |
Shareholders' Equity | 195.14 | 215.99 | 246.11 | 289.23 | 389.61 | 280.79 | Upgrade |
Total Liabilities & Equity | 319.52 | 349.6 | 376.45 | 430.84 | 506.77 | 400.14 | Upgrade |
Total Debt | 64.37 | 65.76 | 70.98 | 87.15 | 42.88 | 22.92 | Upgrade |
Net Cash (Debt) | 170.34 | 201.51 | 210.71 | 249.96 | 408.6 | 348.77 | Upgrade |
Net Cash Growth | -25.76% | -4.37% | -15.70% | -38.82% | 17.16% | 354.13% | Upgrade |
Net Cash Per Share | 2.43 | 2.90 | 4.24 | 5.12 | 8.87 | 30.67 | Upgrade |
Filing Date Shares Outstanding | 71.01 | 70.99 | 68.6 | 49.05 | 48.74 | 43.12 | Upgrade |
Total Common Shares Outstanding | 70.99 | 70.63 | 60.47 | 48.97 | 48.69 | 43.06 | Upgrade |
Working Capital | 191.72 | 212.59 | 228.42 | 243.01 | 274.44 | 337.16 | Upgrade |
Book Value Per Share | 2.75 | 3.06 | 4.07 | 5.91 | 8.00 | 6.52 | Upgrade |
Tangible Book Value | 195.14 | 215.99 | 246.11 | 289.23 | 389.61 | 280.79 | Upgrade |
Tangible Book Value Per Share | 2.75 | 3.06 | 4.07 | 5.91 | 8.00 | 6.52 | Upgrade |
Machinery | 10.37 | 10.37 | 10.18 | 10.66 | 9.48 | 8.41 | Upgrade |
Construction In Progress | - | - | - | 0.18 | - | - | Upgrade |
Leasehold Improvements | 4.71 | 4.71 | 4.71 | 4.68 | 0.54 | 0.54 | Upgrade |
Updated May 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.